Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Kane Biotech Inc > Latest DispersinB news from this week (and last)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(201)
•••
Comment by RoyMax123on Jun 25, 2024 4:19pm
46 Views
Post# 36105772

RE:RE:Latest DispersinB news from this week (and last)

RE:RE:Latest DispersinB news from this week (and last)Someone on CEO answered the same question and it make sense
https://ceo.ca/kne?fa89a80c871f

RoyMax123 wrote: How can they have a deal for something that is not approved and will most likely take several years to have approval ?

francoisl13 wrote: Surprising licensing deal for DispersinB was announced earlier today...see link below;
I-Med Pharma licensing deal announcement

On a less positive note, the DispersinB phase 1 trial was postponed (again) by the FDA, it is now set for H1 2025....not easy to develop new medical device / medication, etc...
The clinical trial with the University of Miami (re.: ACNE) is still on the line for H2 2024.

P.S. We should hear soon about the first shipment of Revyve -- this would definitely put KNE in a new phase of development, commercially speaking..

GLTA




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities